Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 3:15 pm Sale |
2022-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Cormorant Asset Management LP | 1,952,032 8.380% |
-31,136 (-1.57%) |
Filing History |
| 2023-02-13 6:05 pm Purchase |
2022-12-31 | 13G | Elevation Oncology, Inc. ELEV |
BIOTECHNOLOGY VALUE FUND L P | 2,312,200 9.900% |
700,502 (+43.46%) |
Filing History |
| 2023-02-08 5:00 pm Purchase |
2022-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Aisling Capital IV LP | 2,876,561 12.340% |
10,413 (+0.36%) |
Filing History |
| 2022-09-30 5:24 pm Purchase |
2022-07-27 | 13G | Elevation Oncology, Inc. ELEV |
K2 HealthVentures Equity Trust LLC | 1,566,464 6.300% |
1,566,464 (New Position) |
Filing History |
| 2022-09-26 4:21 pm Unchanged |
2021-06-29 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 1,866,339 8.000% |
0 (Unchanged) |
Filing History |
| 2022-07-11 10:28 am Sale |
2022-06-08 | 13G | Elevation Oncology, Inc. ELEV |
DRIEHAUS CAPITAL MANAGEMENT INC | 1,044,244 4.490% |
-458,524 (-30.51%) |
Filing History |
| 2022-06-10 09:02 am Sale |
2022-05-31 | 13G | Elevation Oncology, Inc. ELEV |
DRIEHAUS CAPITAL MANAGEMENT INC | 1,502,768 6.460% |
-479,695 (-24.20%) |
Filing History |
| 2022-05-27 5:26 pm Sale |
2022-05-25 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 1,866,339 8.030% |
-741,828 (-28.44%) |
Filing History |
| 2022-02-14 4:21 pm Sale |
2021-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Boxer Capital LLC | 872,780 3.800% |
-468,750 (-34.94%) |
Filing History |
| 2022-02-14 1:46 pm Purchase |
2021-12-31 | 13G | Elevation Oncology, Inc. ELEV |
BIOTECHNOLOGY VALUE FUND L P | 1,611,698 6.900% |
1,611,698 (New Position) |
Filing History |
| 2022-02-14 12:16 pm Purchase |
2021-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Aisling Capital IV LP | 2,866,148 12.330% |
2,866,148 (New Position) |
Filing History |
| 2022-02-14 09:19 am Purchase |
2021-12-31 | 13G | Elevation Oncology, Inc. ELEV |
DRIEHAUS CAPITAL MANAGEMENT INC | 1,982,463 8.540% |
1,982,463 (New Position) |
Filing History |
| 2022-02-08 4:15 pm Purchase |
2021-06-29 | 13G | Elevation Oncology, Inc. ELEV |
Qiming U.S. Healthcare GP II LLC | 2,370,142 10.200% |
2,370,142 (New Position) |
Filing History |
| 2022-01-18 4:00 pm Purchase |
2021-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Vertex Global HC Fund II Pte. Ltd. | 2,307,642 9.940% |
2,307,642 (New Position) |
Filing History |
| 2021-07-09 4:31 pm Purchase |
2021-06-29 | 13G | Elevation Oncology, Inc. ELEV |
Boxer Capital LLC | 1,341,530 5.900% |
1,341,530 (New Position) |
Filing History |
| 2021-07-09 4:06 pm Purchase |
2021-06-29 | 13G | Elevation Oncology, Inc. ELEV |
Cormorant Asset Management LP | 1,983,168 8.690% |
1,983,168 (New Position) |
Filing History |
| 2021-07-09 4:01 pm Purchase |
2021-06-29 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 2,608,167 11.430% |
2,608,167 (New Position) |
Filing History |